Thrombolytic therapy in children.
Thrombolysis is increasingly considered a treatment option in newborns and children with arterial and venous thromboembolic events, or occluded central venous lines. However, no uniform recommendations are available with regard to indications, drug of choice, route of administration, and dosing regimen. Thus, several protocols are used for the different thrombolytic agents, leading to differing outcome with respect to the effectiveness of therapy and bleeding complications. This article will summarize the available information on the use of thrombolytic agents in newborns and children, focussing on the potential indications, efficacy and safety profiles, and evidence supporting dosing schedules.
Albisetti
Manuela
M
Division of Hematology, University Children's Hospital, Steinwiesstrasse 75, CH-8032 Zurich, Switzerland. manuela.albisetti@kispi.unizh.ch
D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D010960:Plasminogen Activators / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control
D005343:Fibrinolytic Agents; D010960:Plasminogen Activators